sirváis

Sirváis is an in-vitro fertilization technique developed in France in the 1980s. The procedure involves surgical collection of immature eggs, or oocytes, from the ovaries of the female partner. These eggs are then matured in the laboratory using hormone replacement therapy.

After maturation, the eggs are fertilized with sperm, either from the male partner or a donor. The resulting embryos are cultured for several days and then transferred to the uterus, where they implant and develop into a fetus.

Sirváis is an alternative to conventional IVF, typically recommended for women under 35 with low egg reserves or those with poor IVF response. Studies suggest that oocyte maturation in the laboratory can improve egg quality and fertilization rates.

However, the procedure involves risks associated with surgery, including infection and ovarian damage. Additionally, there is limited data available on the long-term outcomes and safety of sirváis. The American Society for Reproductive Medicine (ASRM) notes that the available data are not sufficient to support a general recommendation for or against the use of sirváis.

Several studies have investigated the effectiveness and safety of sirváis, with varying results. Some show improved success rates and lower costs compared to conventional IVF, while others report decreased egg and embryo quality.

Research continues to explore the benefits and limitations of sirváis as a reproductive option. Ongoing studies will help to determine its safety and efficacy in a wider range of patients. The technique is available in certain fertility clinics internationally but is not widely practiced or supported by mainstream medical organizations.